Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib Plus Quercetin for Accelerated Aging in Mental Disorders
NCT05838560Phase 2Active, not recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Jul 2023
- Primary completion
- Oct 2027
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of dasatinib, quercetin in schizophrenia, treatment-resistant depression (TRD), Hutchinson-Gilford progeria syndrome (HGPS), sponsored by Washington University School of Medicine. Started Jul 2023; status: active, not recruiting.
02
Drugs
dasatinibquercetin
03
Conditions
schizophreniatreatment-resistant depression (TRD)Hutchinson-Gilford progeria syndrome (HGPS)
Beyond the preview
Go deeper on NCT05838560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05838560.